Studies have shown that KRAS mutation in NSCLC is significantly correlated with PD-L1 positive (Schoenfeld et al., 2020), and KRAS/TP53 co-mutation in lung adenocarcinoma is associated with higher TMB (Xiang et al., 2020). Here, KRAS is linked to non-small cell lung carcinoma.